CAS: 1254032-66-0; (S)-4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-yl)Benzyl 2,4-Dimethylbenzoate

该化合物是一个复杂的有机化合物,其特点是多功能结构,具有复杂的有机化合物,其特征是用苯并酸盐混合物替代的苯基组,这有利于其作为酯类的潜力.氨甲基基甲基组和异硫衍生物的存在表明,该化合物可能表现出生物活动,可能作为一种药剂或研究化学品.[1S]配置表明,该化合物具有明确的空间安排,可以显著影响其活动性和与生物目标的相互作用.此外,该化合物在结构中存在多个甲基组,可能会增加脂性,影响溶性与易感性和易感性.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-7321046-B2
    优先权日:2002-09-06
    标 题 :Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof
    发明人:CURRAN DENNIS P; SHIN YOUSEUNG; FOURNIER JEAN-HUGUES; MANCUSO JOHN; DAY BILLY W; BRUCKNER ARNDT; FUKUI YOSHIKAZU
    权利人:UNIV PITTSBURGH
    摘要:Dictyostatin and its analogs show great promise as new anticancer agents. The present invention provides dictyostatin analogs, synthetic intermediates for the synthesis of dictyostatin analogs, and synthetic methods for the synthesis of such analogs and intermediates. Dictyostatin analogs can have the following structure or its enantiomer n nwherein R 1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom; R 2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, —SiR a R b R c , CH 2 OR d , or COR e ; R a , R b and R c are independently an alkyl group or an aryl group; R d is an alkyl group, an aryl group, an alkoxylalkyl group, —R i SiR a R b R c or a benzyl group, wherein R i is an alkylene group; R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or —NR g R h , wherein R g and R h are independently H, an alkyl group or an aryl group; R 3 is (CH 2 ) n where n is and integer in the range of 0 to 5, —CH 2 CH(CH 3 )—, —CHâ•?CH—, —CHâ•?C(CH 3 )—, or —C≡C—; R 4 isn n nwherein R 23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, —SiR a R b R c , CH 2 OR d , or COR e ; R 23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, —SiR a R b R c , CH 2 OR d , or COR e , or R 23a and R 23b together form a portion of six-membered acetal ring incorporating CR t R u ; R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group; and R 5 is H or OR 2b , wherein R 2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, —SiR a R b R c , CH 2 OR d , or COR e ; provided that the compound is not dictyostatin 1.

    专利号:US-2007082039-A1
    优先权日:2004-10-18
    标题 :Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
    发明人:JONES GERALD S JR; ST LAURENT JOSEPH P; GOODRICH SCOTT A
    权利人:JONES GERALD S JR; ST LAURENT JOSEPH P; GOODRICH SCOTT A
    摘要:The present invention provides a novel approach for the preparation of fatty alcohol esters of α-hydroxy carboxylic acids. The present invention also provides a novel topical gel for the transdermal delivery of steroids using the fatty alcohol esters as permeation enhancers.

    专利号:US-2002058286-A1
    优先权日:1999-02-24
    标 题 :Synthesis of epothilones, intermediates thereto and analogues thereof
    发明人:DANISHEFSKY SAMUEL J; STACHEL SHAWN J; LEE CHUL BOM; CHAPPELL MARK D; CHOU TING-CHAO; WU ZHICAI
    摘要:The present invention provides convergent processes for preparing epothilones, desoxyepothilones, and analogues thereof. The present invention further provides novel compositions and methods for the treatment of cancer and additionally provides methods for the treatment of cancer which has developed a multi-drug phenotype.

    专利号:US-10550087-B2
    优先权日:2015-11-17
    标 题:Process for the preparation of kinase inhibitors and intermediates thereof
    发明人:STURDIVANT JILL MARIE; DELONG MITCHELL A; CHAMBOURNIER GILLES; PAMMENT MICHAEL G; FEDIJ VICTOR
    权利人:AERIE PHARMACEUTICALS INC
    摘要:Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.

    专利号:US-9643927-B1
    优先权日:2015-11-17
    标题:Process for the preparation of kinase inhibitors and intermediates thereof
    发明人:STURDIVANT JILL M; DELONG MITCHELL A; CHAMBOURNIER GILLES; PAMMENT MICHAEL G; FEDIJ VICTOR
    权利人:AERIE PHARMACEUTICALS INC
    摘要:Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.

    专利号:US-6867305-B2
    优先权日:1996-12-03
    标题:Synthesis of epothilones, intermediates thereto and analogues thereof
    发明人:DANISHEFSKY SAMUEL J; STACHEL SHAWN J; LEE CHUL BOM; CHAPPELL MARK D; WU ZHICAL
    权利人:SLOAN KETTERING INST CANCER; UNIV COLUMBIA
    摘要:The present invention provides convergent processes for preparing epothilones, desoxyepothilones, and analogues thereof. The present invention further provides novel compositions and methods for the treatment of cancer and additionally provides methods for the treatment of cancer which has developed a multi-drug phenotype.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ploysangam P, Patel SP. A Case Report Illustrating the Postoperative Course of Descemetorhexis without Endothelial Keratoplasty with Topical Netarsudil Therapy. Case Rep Ophthalmol Med. 2019 Oct 13;2019:6139026. doi: 10.1155/2019/6139026. eCollection 2019.
    2: Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye (Lond). 2019 Nov 6. doi: 10.1038/s41433-019-0671-0. [Epub ahead of print] Review. doi: 10.1358/dot.2019.55.9.3039670. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. Am J Ophthalmol. 2019 Nov;207:248-257. doi: 10.1016/j.ajo.2019.06.016. Epub 2019 Jun 21. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019 Aug;204:97-104. doi: 10.1016/j.ajo.2019.03.002. Epub 2019 Mar 9. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). Am J Ophthalmol. 2019 Apr;200:130-137. doi: 10.1016/j.ajo.2019.01.003. Epub 2019 Jan 15. doi: 10.2147/OPTH.S154001. eCollection 2018. Review.
    9: Fernandez MM. Reticular Epithelial Edema in Edematous Corneas Treated with Netarsudil. Ophthalmology. 2018 Nov;125(11):1709. doi: 10.1016/j.ophtha.2018.08.004. doi: 10.1358/dot.2018.54.8.2849627. Review. Available from http://www.ncbi.nlm.nih.gov/books/NBK513055/ doi: 10.1089/jop.2017.0138. Epub 2018 Feb 22.

    合成参考文献


    参考文献:10.1186/s13287-021-02611-3
    摘要:Smeringaiova I, Utheim TP, Jirsova K. Ex vivo expansion and characterization of human corneal endothelium for transplantation: a review. Stem Cell Research & Therapy. 2021 Oct 30;12(1):554. doi: 10.1186/s13287-021-02611-3.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知